Peptide Initiative

Peptides · Peptide comparison

Semaglutide vs Tirzepatide

The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.

The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangeSemaglutide0.5–1 mgTirzepatide5–10 mg
FrequencySemaglutideOnce weeklyTirzepatideOnce weekly
AdministrationSemaglutideSubcutaneous injectionTirzepatideSubcutaneous injection
Cycle lengthSemaglutideOngoing/indefiniteTirzepatideOngoing/indefinite
Onset speedSemaglutideModerate (1-2 weeks)TirzepatideModerate (1-2 weeks)
Evidence levelSemaglutideStrong human trials (Phase 3 or FDA approved)TirzepatideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Weight Loss

Semaglutide98%
Tirzepatide99%

Appetite Control

Semaglutide95%
Tirzepatide97%

Heart Protection

Semaglutide92%
TirzepatideNo recorded rating

Blood Sugar Control

SemaglutideNo recorded rating
Tirzepatide96%

Technical data

Compound specifications

Semaglutide

Molecular formula
C187H291N45O59
Molecular weight
4113.58 g/mol
Half-life
Approximately 7 days (168 hours)
Bioavailability
89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)
CAS number
910463-68-2

Tirzepatide

Molecular formula
C225H348N48O68
Molecular weight
4813.45 g/mol
Half-life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS number
2023788-19-2

Protocols

Dosing compared

Semaglutide

Subcutaneous

  • 4 weeks0.25 mgOnce weekly · 4 weeksThis is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up [5].
  • At least 4 weeks at each step0.5-1 mgOnce weekly · At least 4 weeks at each stepAfter the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase [5].
  • Ongoing/maintenance2-2.4 mgOnce weekly · Ongoing/maintenanceThe highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) [5]; up to 2.4 mg is used for weight management (Wegovy) after a slower titration.

Oral

  • 30 days3 mgOnce daily · 30 daysThe pill form (Rybelsus) starts at 3 mg each morning for 30 days. Like the starter shot, this dose is for getting started and does not control blood sugar by itself. Take on an empty stomach with a small sip of water, 30 minutes before food or other pills [6].
  • 30+ days7 mgOnce daily · 30+ daysAfter the first 30 days, the dose increases to 7 mg once daily. This is the first dose that actively lowers blood sugar [6].
  • Ongoing/maintenance14 mgOnce daily · Ongoing/maintenanceThe highest pill dose, used if more blood sugar control is needed after at least 30 days at 7 mg [6].

Tirzepatide

Subcutaneous injection

  • First 4 weeks2.5 mgOnce weekly · First 4 weeksFDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
  • Increase by 2.5 mg after at least 4 weeks at each dose5-10 mgOnce weekly · Increase by 2.5 mg after at least 4 weeks at each dosePer FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
  • Ongoing maintenance12.5-15 mgOnce weekly · Ongoing maintenance15 mg is the maximum FDA-labeled dose [5]. SURMOUNT-1 used up to 15 mg weekly for obesity [1].

Applications

Best suited for

Semaglutide

People with Obesity Seeking Significant Weight Loss
If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. [7] Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds [1].
Those Who've Struggled with Diet and Exercise Alone
Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less [3][7][13].
People with Type 2 Diabetes Needing Better Control
Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. [3][5] It can often allow people to reduce or eliminate other diabetes medications [21].
Individuals at High Cardiovascular Risk
The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes [2].

Tirzepatide

People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close [1].
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss [2][9].
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health [2].
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you [11].

Safety profile

Side effects

Semaglutide

Common

  • Nausea
  • Constipation or Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Loss (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Tirzepatide

Common

  • Nausea
  • Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Thinning (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Research status

Safety & evidence

Semaglutide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. [1][2][8][9][10] The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. [1][7] The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss [2].

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) [7]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [7]
  • History of serious allergic reaction to semaglutide [7]

Tirzepatide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. [1][2][3] The FDA approved it after thorough safety review. [5][6] While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. [5][6] Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes. [16]

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) [6]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [6]
  • History of serious allergic reaction to tirzepatide [6] or any GLP-1/GIP medication

Decision guide

Which is right for you?

Semaglutide

Choose Semaglutide if…

  • Significant weight loss
  • Long-term weight management
  • Cardiovascular risk reduction
  • Blood sugar control

Tirzepatide

Choose Tirzepatide if…

  • Maximum weight loss results
  • Long-term obesity management
  • Type 2 diabetes control
  • Metabolic health improvement